Precision BioSciences Receives Approval to Expand Hepatitis B Clinical Trials in Europe

Key Facts

1Precision BioSciences received Clinical Trial Application (CTA) approval to expand its ELIMINATE-B clinical trial into France and Spain.

2The company utilizes its proprietary ARCUS platform to develop in vivo gene editing therapies for chronic hepatitis B.

Precision BioSciences (Nasdaq: DTIL) has received Clinical Trial Application (CTA) approval to expand its ELIMINATE-B clinical trial into France and Spain. This expansion aims to accelerate the global clinical development of PBGENE-HBV, a candidate targeting chronic hepatitis B. The company utilizes its proprietary ARCUS platform to develop advanced in vivo gene editing therapies. Expanding into major European markets represents a significant operational milestone for the biotech firm, providing access to a broader patient demographic. This regulatory progress is an incremental but positive step in the company's long-term clinical strategy. The move underscores the growing global footprint of Precision BioSciences in the competitive gene-editing landscape.